Raynaud’s phenomenon caused by cabergoline during the treatment of a macroprolactinoma: a case report

Abstract

Digital vasospasm is a known adverse effect of dopamine agonists such as bromocriptine; however, it has rarely been reported with cabergoline. We describe a case of Raynaud's phenomenon as a side effect of treatment with the latter in a 52-year-old woman with a macroprolactinoma, forcing discontinuation. In this context, we conducted a review of the literature, with emphasis on the possible criteria for discontinuation of treatment with dopaminergic agonists in patients with macroprolactinoma.